A randomized, double-blind, phase II study of MK-4280A (coformulation of favezelimab and pembrolizumab) plus lenvatinib versus pembrolizumab plus lenvatinib among patients with previously-treated mismatch repair proficient advanced endometrial cancer.

Bibliographic Details
Title: A randomized, double-blind, phase II study of MK-4280A (coformulation of favezelimab and pembrolizumab) plus lenvatinib versus pembrolizumab plus lenvatinib among patients with previously-treated mismatch repair proficient advanced endometrial cancer.
Authors: Girda, Eugenia1 (AUTHOR), Makker, Vicky2 (AUTHOR), Marth, Christian3 (AUTHOR), Van Gorp, Toon4 (AUTHOR), Mirza, Mansoor5 (AUTHOR), Shapira-Frommer, Ronnie6 (AUTHOR), Suttner, Leah7 (AUTHOR), Groisberg, Roman7 (AUTHOR), Jin, Fan7 (AUTHOR), O'Malley, David8 (AUTHOR)
Source: Gynecologic Oncology. 2024 Supplement 1, Vol. 190, pS293-S294. 2p.
Subject Terms: *ENDOMETRIAL cancer, *PEMBROLIZUMAB
Database: Academic Search Complete
More Details
ISSN:00908258
DOI:10.1016/j.ygyno.2024.07.438
Published in:Gynecologic Oncology
Language:English